Bahadori A, Wilhelm-Bals A, Caccia J, Chehade H, Goischke A, Habre C
Children (Basel). 2025; 11(12.
PMID: 39767990
PMC: 11726877.
DOI: 10.3390/children11121561.
Wedderburn C, Evans C, Slogrove A, Rehman A, Gibb D, Prendergast A
J Int AIDS Soc. 2023; 26(6):e26079.
PMID: 37292018
PMC: 10251133.
DOI: 10.1002/jia2.26079.
Mahmood I
J Clin Transl Res. 2022; 8(5):369-381.
PMID: 36518546
PMC: 9741938.
Paneth N, Joyner M, Casadevall A
J Clin Invest. 2022; 132(4).
PMID: 35166241
PMC: 8843741.
DOI: 10.1172/JCI158499.
Gould A, Winders H, Stover K, Bookstaver P, Griffin B, Bland C
Drugs Context. 2021; 10.
PMID: 34603460
PMC: 8462995.
DOI: 10.7573/dic.2021-4-3.
Pregnancy and medications in inflammatory bowel disease.
Cao R, Grimm M
Obstet Med. 2021; 14(1):4-11.
PMID: 33995565
PMC: 8107959.
DOI: 10.1177/1753495X20919214.
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke D, Acosta E, Cababasay M, Wang J, Chain A, Teppler H
J Acquir Immune Defic Syndr. 2020; 84(1):70-77.
PMID: 31913995
PMC: 7144886.
DOI: 10.1097/QAI.0000000000002294.
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
Clarke D, Mirochnick M, Acosta E, Capparelli E, Chain A, Teppler H
J Acquir Immune Defic Syndr. 2019; 82(4):392-398.
PMID: 31658182
PMC: 6820708.
DOI: 10.1097/QAI.0000000000002149.
Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease.
Riordan S, Shapiro S
Pediatr Res. 2019; 87(2):327-331.
PMID: 31600770
DOI: 10.1038/s41390-019-0608-0.
Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.
Strauss K, Ahlfors C, Soltys K, Mazareigos G, Young M, Bowser L
Hepatology. 2019; 71(6):1923-1939.
PMID: 31553814
PMC: 7909716.
DOI: 10.1002/hep.30959.
The Challenges of Pediatric Drug Development.
Rose K
Curr Ther Res Clin Exp. 2019; 90:128-134.
PMID: 31388368
PMC: 6677568.
DOI: 10.1016/j.curtheres.2019.01.007.
Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia.
Rose K, Neubauer D, Grant-Kels J
Curr Ther Res Clin Exp. 2019; 90:86-91.
PMID: 31388360
PMC: 6677645.
DOI: 10.1016/j.curtheres.2019.01.002.
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.
Lommerse J, Clarke D, Kerbusch T, Merdjan H, Witjes H, Teppler H
CPT Pharmacometrics Syst Pharmacol. 2019; 8(9):643-653.
PMID: 31215170
PMC: 6765695.
DOI: 10.1002/psp4.12443.
Pediatric melanoma-The whole (conflicts of interest) story.
Rose K, Grant-Kels J
Int J Womens Dermatol. 2019; 5(2):110-115.
PMID: 30997384
PMC: 6451736.
DOI: 10.1016/j.ijwd.2018.10.020.
Studying the Evolving Knowledge of Adverse Drug Reactions in Order to Facilitate the Rational Use of Medicines in Paediatric Patients.
Star K, Choonara I
Healthcare (Basel). 2019; 7(2).
PMID: 30987039
PMC: 6628330.
DOI: 10.3390/healthcare7020055.
Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.
Germovsek E, Barker C, Sharland M, Standing J
Clin Pharmacokinet. 2018; 58(1):39-52.
PMID: 29675639
PMC: 6325987.
DOI: 10.1007/s40262-018-0659-0.
Pediatric Melanoma and Drug Development.
Rose K, Grant-Kels J
Children (Basel). 2018; 5(3).
PMID: 29558389
PMC: 5867502.
DOI: 10.3390/children5030043.
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli R, Back D, Rannard S, Meyers C, Flexner C, Owen A
Clin Pharmacokinet. 2017; 57(2):255-266.
PMID: 28540638
PMC: 5701864.
DOI: 10.1007/s40262-017-0557-x.
Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial.
Lockman S, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S
Lancet Glob Health. 2017; 5(5):e491-e500.
PMID: 28395844
PMC: 5502726.
DOI: 10.1016/S2214-109X(17)30143-2.
Getting to 90-90-90 in paediatric HIV: What is needed?.
Davies M, Pinto J, Bras M
J Int AIDS Soc. 2017; 18(7Suppl 6):20770.
PMID: 28326130
PMC: 4813611.
DOI: 10.7448/IAS.18.7.20770.
